Fly News Breaks for October 17, 2019
ABT, TNDM
Oct 17, 2019 | 09:02 EDT
Lake Street analyst Brooks O'Neil believes Tandem Diabetes' (TNDM) partnership with Abbott (ABT) offers the company "substantial opportunity." Abbott's Libre opens a "huge incremental opportunity" for Tandem both in the U.S. and around the world, O'Neil tells investors in a research note. In addition, the deal likely opens the "door wide" for further positive reimbursement decisions for Tandem, contends the analyst. He keeps a Buy rating on Tandem Diabetes with a $100 price target.
News For TNDM;ABT From the Last 2 Days
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.